Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML-VAC-XS15 Vaccine in AML Patients in Complete Remission
NCT06252584Phase 1Not yet recruiting
- Sponsor
- University Hospital Tübingen
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Peptide-based Cancer Vaccines
01
Overview
Phase 1, open-label, single-arm trial of AML-VAC-XS15 in acute myeloid leukemia (AML), sponsored by University Hospital Tübingen. Primary endpoint: Immunogenicity at Day 250. Planned start May 2024; status: not yet recruiting.
02
Drugs
AML-VAC-XS15
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06252584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252584.